Listed by the USPTO as ROZOF, TIMOTHY R
Tech Center 1600 • Art Units: 1625
This examiner grants 73% of resolved cases
ROZOF, TIMOTHY R has 983 resolved cases in Tech Center 1600 and Art Unit 1625. The allowance rate is 72.6%, and the interview lift is 23.4%, indicating that interviews are associated with improved allowance outcomes. The median time to allowance is 739 days, providing a relatively defined timing reference for prosecution planning.
The principal companies are Fujifilm Holdings Corporation, Janssen Pharmaceutica NV, and The Regents of the University of California. The leading firms are FOLEY HOAG, LLP (General), OBLON, MCCLELLAND, MAIER & NEUSTADT, L.L.P., and BakerHostetler. Practitioners may find interviews useful for resolving issues before further prosecution steps, while retaining a disciplined written record.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18967488 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | Non-Final OA | ANTECIP BIOVENTURES II LLC |
| 18886532 | ANTIVIRAL PRODRUGS, PHARMACEUTICAL FORMULATIONS, AND METHODS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18885092 | COMPOUND AND LIPID COMPOSITION | Non-Final OA | FUJIFILM Corporation |
| 18447057 | METHOD AGAINST SNAKE ENVENOMATION | Final Rejection | National Tsing Hua University |
| 18837956 | METHODS OF TREATING PROSTATE CANCER | Non-Final OA | AstraZeneca AB |
| 17926424 | A COMPOSITION FOR IMPROVING QOL OF A 40-YEAR-OLD OR OLDER POSTMENOPAUSAL WOMAN WITHOUT MENOPAUSAL DISORDER | Non-Final OA | DAICEL CORPORATION |
| 18266917 | USE OF MGLUR5 ANTAGONISTS FOR TREATING GAMBLING DISORDER | Final Rejection | Yale University |
| 18976869 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | Non-Final OA | Bristol-Myers Squibb Company |
| 18276762 | BODY TEMPERATURE LOWERING AGENT, BODY TEMPERATURE ELEVATION SUPPRESSOR, FOOD COMPOSITION FOR LOWERING BODY TEMPERATURE,AND FOOD COMPOSITION FOR SUPPRESSING BODY TEMPERATURE ELEVATION | Final Rejection | University of Tsukuba |
| 18639526 | METHODS OF TREATING SWI/SNF DEREGULATED CANCERS | Non-Final OA | Fred Hutchinson Cancer Center |
| 18768496 | TREATMENT OF MIGRAINE | Non-Final OA | Allergan Pharmaceuticals International Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy72.6% of resolved applications examined by Timothy R Rozof were allowed (983 resolved cases), compared with 51.3% across Art Unit 1625 over the last five years.
This examiner's interview lift is +23.4 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Timothy R Rozof took 739 days on average from filing to allowance.
Timothy R Rozof examines applications in Art Unit 1625 in Tech Center 1600 (Biotechnology & Pharmaceuticals).